Clinical Trials

Phase 1/2 Not yet recruiting

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07479979 2026-03-23

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

62 enrolled

Phase 1 Not yet recruiting

Multiple Myeloma

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT07334535 2026-01-13

Isa-VRD in TIE HRMM

Phase 4 Not yet recruiting

117 enrolled

Multiple Myeloma

NCT07335887 2026-01-13

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

39 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

23 enrolled

Phase 3 Not yet recruiting

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07285239 2025-12-16

PrE1005

500 enrolled

Phase 4 Not yet recruiting

Multiple Myeloma

NCT07254416 2025-11-28

A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients

120 enrolled

Breast

Breast Cancer Patients Treated With T-DXd

NCT07247097 2025-11-25

ELDORADO

160 enrolled

Multiple Myeloma

NCT07227584 2025-11-12

ALL Backbone in AYAs

67 enrolled

Phase NA Not yet recruiting

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07015021 2025-06-11

DKPD

72 enrolled

Multiple Myeloma

NCT06643689 2024-11-14

TAPES

394 enrolled

Gastrointestinal

Esophageal Neoplasms, Esophageal Stenosis

NCT06175702 2023-12-19

LALPh2022

Not yet recruiting

150 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05909826 2023-06-18

KMM-KCd

49 enrolled

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT05581875 2022-10-17

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

48 enrolled

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT05527340 2022-09-02

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

140 enrolled